MacDonald William, Giordano Thomas J, Leisring Joshua, Parwani Anil, Dedhia Priya H, Phay John, Kirschner Lawrence S, Miller Barbra S
Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH.
Department of Pathology, University of Michigan Health System, Ann Arbor, MI. Electronic address: https://twitter.com/Tom_J-Giordano.
Surgery. 2025 Jan;177:108841. doi: 10.1016/j.surg.2024.06.068. Epub 2024 Oct 11.
How aldosterone synthase (CYP11B2) staining patterns impact patient outcomes in those with unilateral primary aldosteronism is not well described. We hypothesized that a system of categorization would benefit future research and that clinical and biochemical outcomes after unilateral adrenalectomy are impacted by different CYP11B2 staining patterns.
A retrospective review of patients undergoing adrenalectomy for primary aldosteronism from January 2015 to September 2023 was conducted. Demographics, clinical, and pathologic data were analyzed. A system of categorization of staining patterns was developed. Clinical and biochemical outcomes were compared with staining patterns to assess differences and determine correlation. Descriptive and statistical analyses were performed using SPSS.
Forty-three patients were included. The following CYP11B2 staining patterns were identified: (1) single adenoma; (2) aldosterone producing nodule(s) or micronodule(s); (3) combination of type 1 and type 2; (4) hyperplasia; and (5) aldosterone-producing adrenocortical cancer. In total, 23 of 43 revealed CYP11B2 staining in a single adenoma only. Staining in 3/23 involved a portion of the adenoma. 4/9 patients age <40 had areas of CYP11B2 staining in nonadenomatous tissue. Complete biochemical cure was noted in 37 of 43 (86%) and complete clinical cure in 23.2%. There were no differences between staining pattern and sex, race, or age. CYP11B2 staining pattern did not correlate with early clinical or biochemical outcomes.
Adrenalectomy specimens from patients treated for primary aldosteronism reveal multiple CYP11B2 staining patterns, including in nonadenomatous tissue in many patients. The impact of these patterns on clinical outcomes requires additional investigation. Uniform categorization of staining patterns will allow for consistent reporting across studies.
醛固酮合酶(CYP11B2)染色模式如何影响单侧原发性醛固酮增多症患者的预后,目前尚无充分描述。我们推测,一种分类系统将有助于未来的研究,并且单侧肾上腺切除术后的临床和生化结果会受到不同CYP11B2染色模式的影响。
对2015年1月至2023年9月因原发性醛固酮增多症接受肾上腺切除术的患者进行回顾性研究。分析了人口统计学、临床和病理数据。制定了染色模式分类系统。将临床和生化结果与染色模式进行比较,以评估差异并确定相关性。使用SPSS进行描述性和统计分析。
纳入43例患者。确定了以下CYP11B2染色模式:(1)单一腺瘤;(2)醛固酮分泌结节或微结节;(3)1型和2型的组合;(4)增生;(5)醛固酮分泌性肾上腺皮质癌。43例患者中共有23例仅在单一腺瘤中显示CYP11B2染色。23例中有3例的染色累及腺瘤的一部分。9例年龄<40岁的患者中有4例在非腺瘤组织中有CYP11B2染色区域。43例中有37例(86%)实现了完全生化治愈,23.2%实现了完全临床治愈。染色模式与性别、种族或年龄之间无差异。CYP11B2染色模式与早期临床或生化结果无关。
接受原发性醛固酮增多症治疗的患者的肾上腺切除标本显示出多种CYP11B2染色模式,包括许多患者的非腺瘤组织。这些模式对临床结果的影响需要进一步研究。染色模式的统一分类将使各研究之间的报告保持一致。